An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

February 1, 2030

Study Completion Date

February 1, 2030

Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
BIOLOGICAL

Ublituximab

Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.

Trial Locations (86)

10000

TG Investigational Trial Site, Zagreb

10002

TG Therapeutics Investigational Trial Site, Zhytomyr

11000

TG Therapeutics Investigational Trial Site, Belgrade

14001

TG Therapeutics Investigational Trial Site, Chernihiv

14029

TG Therapeutics Investigational Trial Site, Chernihiv

14266

TG Therapeutics Investigational Trial Site, Amherst

18009

TG Therapeutics Investigational Trial Site, Cherkasy

21005

TG Therapeutics Investigational Trial Site, Vinnytsia

31000

TG Therapeutics Investigational Trial Site, Osijek

33136

TG Therapeutics Investigational Trial Site, Miami

33612

TG Therapeutics Investigational Trial Site, Tampa

34000

TG Therapeutics Investigational Trial Site, Kragujevac

36011

TG Therapeutics Investigational Trial Site, Poltava

37922

TG Therapeutics Investigational Trial Site, Knoxville

42000

TG Therapeutics Investigational Trial Site, Varaždin

43081

TG Therapeutics Investigational Trial Site, Westerville

43214

TG Therapeutics Investigational Trial Site, Columbus

46027

TG Therapeutics Investigational Trial Site, Ternopil

48201

TG Therapeutics Investigational Trial Site, Detroit

58002

TG Therapeutics Investigational Trial Site, Chernivtsi

60062

TG Therapeutics Investigational Trial Site, Northbrook

61058

TG Therapeutics Investigational Trial Site, Kharkiv

61103

TG Therapeutics Investigational Trial Site, Kharkiv

61176

TG Therapeutics Investigational Trial Site, Kharkiv

65009

TG Therapeutics Investigational Trial Site, Odesa

66160

TG Therapeutics Investigational Trial Site, Kansas City

69065

TG Therapeutics Investigational Trial Site, Zaporizhia

75034

TG Therapeutics Investigational Trial Site, Frisco

75246

TG Therapeutics Investigational Trial Site, Dallas

76008

TG Therapeutics Investigational Trial Site, Ivano-Frankivsk

78258

TG Therapeutics Investigational Trial Site, San Antonio

78681

TG Therapeutics Investigational Trial Site, Round Rock

79000

TG Therapeutics Investigational Trial Site, Lviv

79010

TG Therapeutics Investigational Trial Site, Lviv

80045

TG Therapeutics Investigational Trial Site, Denver

87131

TG Therapeutics Investigational Trial Site, Albuquerque

88018

TG Therapeutics Investigational Trial Site, Uzhhorod

89106

TG Therapeutics Investigational Trial Site, Las Vegas

91105

TG Therapeutics Investigational Trial Site, Pasadena

96900

TG Therapeutics Investigational Trial Site, Zaporizhia

98109

TG Therapeutics Investigational Trial Site, Seattle

125367

TG Therapeutics Investigational Trial Site, Moscow

127015

TG Therapeutics Investigational Trial Site, Moscow

163045

TG Therapeutics Investigational Trial Site, Arkhangelsk

197002

TG Therapeutics Investigational Trial Site, Saint Petersburg

197110

TG Therapeutics Investigational Trial Site, Saint Petersburg

197376

TG Therapeutics Investigational Trial Site, Saint Petersburg

214018

TG Therapeutics Investigational Trial Site, Smolensk

220114

TG Therapeutics Investigational Trial Site, Minsk

220116

TG Therapeutics Investigational Trial Site, Minsk

220226

TG Therapeutics Investigational Trial Site, Minsk

230017

TG Therapeutics Investigational Trial Site, Grodno

241033

TG Therapeutics Investigational Trial Site, Bryansk

305007

TG Therapeutics Investigational Trial Site, Kursk

320017

TG Therapeutics Investigational Trial Site, Grodno

357538

TG Therapeutics Investigational Trial Site, Pyatigorsk

430032

TG Therapeutics Investigational Trial Site, Saransk

450005

TG Therapeutics Investigational Trial Site, Ufa

454021

TG Therapeutics Investigational Trial Site, Chelyabinsk

603155

TG Therapeutics Investigational Trial Site, Nizhny Novgorod

620102

TG Therapeutics Investigational Trial Site, Yekaterinburg

625000

TG Therapeutics Investigational Trial Site, Tyumen

630007

TG Therapeutics Investigational Trial Site, Novosibirsk

630087

TG Therapeutics Investigational Trial Site, Novosibirsk

634050

TG Therapeutics Investigational Trial Site, Tomsk

650066

TG Therapeutics Investigational Trial Site, Kemerovo

656045

TG Therapeutics Investigational Trial Site, Barnaul

660037

TG Therapeutics Investigational Trial Site, Krasnoyarsk

07666

TG Therapeutics Investigational Trial Site, Teaneck

00112

TG Therapeutics Investigational Trial Site, Tbilisi

00114

TG Therapeutics Investigational Trial Site, Tbilisi

00159

TG Therapeutics Investigational Trial Site, Tbilisi

00160

TG Therapeutics Investigational Trial Site, Tbilisi

00172

TG Therapeutics Investigational Trial Site, Tbilisi

00179

TG Therapeutics Investigational Trial Site, Tbilisi

40-555

TG Therapeutics Investigational Trial Site, Katowice

40-568

TG Therapeutics Investigational Trial Site, Katowice

40-684

TG Therapeutics Investigational Trial Site, Katowice

31-505

TG Therapeutics Investigational Trial Site, Krakow

41-800

TG Therapeutics Investigational Trial Site, Lodz

10-561

TG Therapeutics Investigational Trial Site, Olsztyn

61-583

TG Therapeutics Investigational Trial Site, Poznan

04-141

TG Therapeutics Investigational Trial Site, Warsaw

04-749

TG Therapeutics Investigational Trial Site, Zabrze

03037

TG Therapeutics Investigational Trial Site, Kyiv

03115

TG Therapeutics Investigational Trial Site, Kyiv

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT04130997 - An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter